Literature DB >> 16085423

Microplate filtration assay for nicotinamide release from NAD using a boronic acid resin.

Thomas McDonagh1, Jeffrey Hixon, Peter S DiStefano, Rory Curtis, Andrew D Napper.   

Abstract

We describe a microplate-based assay for NAD-dependent Class III histone deacetylases (also known as SIRTs) that measures the enzyme-catalyzed release of nicotinamide from radiolabeled NAD, using a boronic acid resin to selectively capture the NAD. This method avoids the need for fluorogenic or radiolabeled peptides or separation of the reaction products using solvent extraction. The protocol reported here is rapid and uses commercially available materials. The use of a simple microplate filtration device allows for the simultaneous processing of 96 samples, facilitating enzyme kinetic analyses and inhibition studies. Furthermore, monitoring nicotinamide release rather than peptide deacetylation obviates the need for chemical modification of protein and peptide substrates. This assay is applicable to SIRTs and other enzymes that cleave nicotinamide from NAD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16085423     DOI: 10.1016/j.ymeth.2005.03.005

Source DB:  PubMed          Journal:  Methods        ISSN: 1046-2023            Impact factor:   3.608


  7 in total

Review 1.  Catalysis and mechanistic insights into sirtuin activation.

Authors:  Kristin E Dittenhafer-Reed; Jessica L Feldman; John M Denu
Journal:  Chembiochem       Date:  2010-11-09       Impact factor: 3.164

2.  A continuous microplate assay for sirtuins and nicotinamide-producing enzymes.

Authors:  Brian C Smith; William C Hallows; John M Denu
Journal:  Anal Biochem       Date:  2009-07-16       Impact factor: 3.365

Review 3.  Rejuvenating sirtuins: the rise of a new family of cancer drug targets.

Authors:  Santina Bruzzone; Marco Daniele Parenti; Alessia Grozio; Alberto Ballestrero; Inga Bauer; Alberto Del Rio; Alessio Nencioni
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

4.  Synthesis and evaluation of substituted chroman-4-one and chromone derivatives as sirtuin 2-selective inhibitors.

Authors:  Maria Fridén-Saxin; Tina Seifert; Marie Rydén Landergren; Tiina Suuronen; Maija Lahtela-Kakkonen; Elina M Jarho; Kristina Luthman
Journal:  J Med Chem       Date:  2012-08-07       Impact factor: 7.446

5.  Improved mass spectrometry-based activity assay reveals oxidative and metabolic stress as sirtuin-1 regulators.

Authors:  Di Shao; Chunxiang Yao; Maya H Kim; Jessica Fry; Richard A Cohen; Catherine E Costello; Reiko Matsui; Francesca Seta; Mark E McComb; Markus M Bachschmid
Journal:  Redox Biol       Date:  2019-03-05       Impact factor: 11.799

6.  Over expression of wild type or a catalytically dead mutant of Sirtuin 6 does not influence NFκB responses.

Authors:  Rachel Grimley; Oxana Polyakova; Jessica Vamathevan; Joanne McKenary; Brian Hayes; Champa Patel; Janet Smith; Angela Bridges; Andrew Fosberry; Anshu Bhardwaja; Bernadette Mouzon; Chun-Wa Chung; Nathalie Barrett; Nicola Richmond; Sundip Modha; Roberto Solari
Journal:  PLoS One       Date:  2012-07-06       Impact factor: 3.240

7.  Continuous Activity Assay for HDAC11 Enabling Reevaluation of HDAC Inhibitors.

Authors:  Zsófia Kutil; Jana Mikešová; Matthes Zessin; Marat Meleshin; Zora Nováková; Glenda Alquicer; Alan Kozikowski; Wolfgang Sippl; Cyril Bařinka; Mike Schutkowski
Journal:  ACS Omega       Date:  2019-11-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.